Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure

Exclusion Criteria

• •1. Received any investigational agent or participation in any clinical study of an investigational agent or investigational therapy up to 30 days prior to the screening visit.
• •2. Use of any new prescription medication up to 14 days prior to receiving investigational drug.
• •3. Patients with known specific hepatic disease; bilirubin \>2 mg/dL, SGOT \> 100 IU.
• •4. Patients with a history of hepatic impairment (hepatitis B and C).
• •5. Serum creatinine \>2.5 mg/dL.
• •6. Documented stroke or transient ischemic attack (TIA) within 60 days of study enrollment.